• LATEST NEWS: The only conference in Australia offering multidisciplinary insights into the complex nature of pain management from a variety of medical, nursing and allied health perspectives.
  • bioCSL

    bioCSL
  • Mundipharma

    Mundipharma
  • Pfizer

    Pfizer
  • Indivior

    Indivior
  • Reckitt Benckiser - Health, Home and Hygiene

    Reckitt Benckiser - Health, Home and Hygiene
  • bioCSL

    bioCSL
  • Mundipharma

    Mundipharma
  • bioCSL

    bioCSL
  • Indivior

    Indivior
  • Mundipharma

    Mundipharma
  • Pfizer

    Pfizer
  • Reckitt Benckiser - Health, Home and Hygiene

    Reckitt Benckiser - Health, Home and Hygiene

2015 Australian Pain Society
35th Annual Scientific Meeting

2015 Australian Pain Society
35th Annual Scientific Meeting

APS BLOG LATEST POSTS

    An error occurred while trying to process .
    Please contact the webmaster.

Sponsored Sessions

Click on the following titles to read about each breakfast session:

Mundipharma - Monday Breakfast

Nevro - Monday Breakfast 

Indivior - Monday Afternoon

BioCSL - Tuesday Breakfast

Pfizer - Tuesday Breakfast

Reckitt Benckiser - Health, Home and Hygiene - Wednesday Breakfast

Orthocell - Wednesday Breakfast

 Monday 16 March 2015, 7.30 - 8.30 am

The complexities, comorbidities and consequences of pharmaceutical opioids: An overview of the Australian situation and early findings of post-marketing surveillance of a potentially abuse-deterrent formulation of oxycodone

There has been increasing concern in the community and among health professionals about the misuse of pharmaceutical opioids, and their potential for harm. There has been a considerable increase in the long-term prescribing of opioids for chronic non-cancer pain (CNCP) in a number of countries, including but not limited to the United States, Canada and Australia. There has also been increasing concern in a about concomitant increases problematic opioid use and related harms including injection, problematic use and dependence, and overdose.

Professor Louisa Degenhardt first commenced work at the National Drug and Alcohol Research Centre (NDARC), Faculty of Medicine, UNSW in 1998 and has worked across a wide range of projects examining the epidemiology of illicit drug use, comorbid mental health problems, and illicit drug surveillance. Her PhD, completed in 2001, examined the comorbidity of drug use and mental health problems in the Australian population. Louisa has published over 310 peer reviewed papers, 110 technical reports and monographs, three books and 35 book chapters. From 2001 to 2008 she established and expanded national drug surveillance and strategic early warning systems across Australia. Professor Degenhardt was the lead academic on the Secretariat for the Reference Group to the United Nations on Injecting Drug Use and HIV (2007-2010) and continues to work with WHO and UNAIDS examining epidemiology of illicit drug use and associated health risks across the globe. She co-chaired the Expert Group on mental disorders and illicit drug use for the 2010 Global Burden of Disease study and is on the core analytic team for GBD 2.0.

Advances in Spinal Cord Stimulation: (HF10 Technology and Latest Results from Randomized Clinical Trial)
10kHz High-Frequency Spinal Cord Stimulation (SCS), HF10, is a major advance in neuromodulation for chronic pain. A large, randomized clinical trial (RCT) has been conducted in the United States to evaluate this advanced technology.The landmark study provides the first Level 1 evidence for SCS for chronic back pain. Dr. Leo Kapural and Dr. Kasra Amirdelfan, leading experts on neuromodulation and investigators of this study, will be presenting. This session will inform the audience of an advanced SCS technology and the first Level 1 evidence for SCS for back pain, which have important applicability to physicians for treating patients with few options.

 Dr. Kasra Amirdelfan, MD is one of the founding partners at Integrated Pain Management, Inc., in Walnut Creek, California.  Dr. Amirdelfan completed his fellowship in interventional pain management at Pacific Pain Treatment Centers with Dr. Elliot Krames, in collaboration with California Pacific Medical Centers in San Francisco.  He lectures extensively on spinal cord stimulation and pain management and is regarded as one of the foremost thought leaders in the pain management community. He also continues to be actively involved in conducting research for the development of new technologies and has special interests in Spinal diseases, spinal cord stimulation, and stem cell technologies.

Dr Leo KapuralMD, PhD is the Medical Director of the Chronic Pain Center at Wake Forest University Health Sciences in Winston-Salem, North Carolina.  Dr. Kapural completed residency at the Cleveland Clinic's Division of Anesthesiology and Critical Care in Cleveland, OH and Fellowship in Pain Management at the Cleveland Clinic.  He was listed by his peers in the “Best Doctors in America.”  He has published more than 150 journal articles and abstracts and 20 book chapters regarding his interests, which center on discogenic low back pain, visceral abdominal pain, and spinal cord/peripheral nerve stimulation.

 

Monday 16 March 2015, 5.15 - 6.15 pm, Canapes to follow




The abuse, misuse and dependence of prescription opioids – issues and challenges

This session will briefly outline the increasing issue of prescription opioid drug abuse, and the challenge of identifying patients who lose control of their medication and, subsequently develop an opioid substance use disorder. The focus will be on identification of problematic prescription use, the challenges in raising the issue with patients, and discussion of available treatment options including Medication Assisted Treatment.

Dr Christian Rowan is an Addiction Medicine Specialist with a strong associated interest in Pain Management. He is the Medical Director of Addiction Sciences Queensland and is a Fellow of the Royal Australasian College of Physicians' Chapter of Addiction Medicine. He is also a member of the Australasian Professional Society on Alcohol and Other Drugs. Dr Rowan is a Visiting Medical Officer to the St Andrew's War Memorial Hospital Multidisciplinary Pain Service and to the Wesley Pain and Spine Centre. He has worked in a number of Alcohol, Tobacco and Other Drug Services, including at the Roma Street Clinic (Biala), the Peel Street Clinic, and Logan Central Community Health. Dr Rowan’s clinical interests include prescription drug dependency, opioid substitution therapy, and co-morbidity pertaining to pain conditions and substance disorders. Dr Rowan is an Associate Professor in the School of Medicine at Griffith University. He is a Board Member of the Wesley-St Andrew's Research Institute. He is a member of the Queensland Mental Commission’s Mental Health & Drug Advisory Council.

Tuesday 17 March 2015, 7.30 - 8.30 am

Pain intensity vs. functional improvement…time to shift our thinking
This clinically orientated symposium challenges the place of ‘pain intensity’ as the primary measure of analgesic efficacy when treating chronic pain patients. Improving function is a shared treatment goal of multidisciplinary pain management plans with pharmacological based analgesia playing an important role in achieving this goal.  Therefore this symposium will question if we should be measuring the analgesia of drugs based on quality of life improvements such as function instead of pain relief?
In exploring this topic an overview of the clinical data for Palexia SR will be presented and discussed in relation to functioning and quality of life including several case-based presentations.

 

 Dr Michael Vagg is a consultant in rehabilitation and pain medicine. He graduated from Monash University in 1994 and spent several years as a uniformed Medical Officer in the RAAF before undertaking vocational training. Dr Vagg completed a Fellowship of the AFRM in 2004. He subsequently gained Fellowship of the FPM of the Australian and New Zealand College of Anaesthetists in 2006. Apart from being a Director of Pain Matrix, he is also a Visiting Medical Specialist at Barwon Health Pain Management Unit and McKellar Centre for Rehabilitation in Geelong. He holds an appointment as Clinical Senior Lecturer in Musculoskeletal Medicine at Deakin University School of Medicine. For the FPM, he is Chair of the CPD Committee and Board Member representing the AFRM. He is also an executive member of the AFRM SIG in musculoskeletal, pain and occupational rehabilitation.

Dr Marc Russo is the Director of the Hunter Pain Clinic, Hamilton Day Surgery, Hunter Clinical Research and Co-Director of the Innervate Pain Management Program in Newcastle NSW Australia.  He founded the Hunter Pain Clinic in 1999, Hamilton Day Surgery in 2001, Hunter Specialist Medical Centre 2003, Hunter Clinical Research in 2005.  He also founded NAPS (Newcastle Anaesthetic Peri-operative Services). Dr Russo specialises in spinal cord stimulator implantation and completed two successful world’s first Spinal Cord Stimulator device implantations Newcastle Australia in 2011 establishing him as a leader in his field. He instigates Intrathecal analgesia and other interventional pain medicine approaches including a combination of pharmacotherapy and systems approaches.  

Putting neuropathic pain guidelines into practice
In the IASP year against neuropathic pain, join Professor Stephan Schug as he discusses  the diagnostic protocols and evidence based treatment for neuropathic pain with Professor Rainer Freynhagen via weblink from Germany. 

Professor  Rainer Freynhagen, Department of Anaesthesiology, Critical Care Medicine, Pain Therapy & Palliative Care; Pain Centre Lake Starnberg, Benedictus Krankenhaus Tutzing, Academic Teaching Hospital of the Technical University Munich, Germany. Professor Freynhagen MD, D.E.A.A., is a specialist in Anaesthesiology, Intensive Care, Pain Management, Palliative Care  and Sports Medicine. In 2009 he was elected head of the Dept of Anaesthesiology, Critical Care Medicine, Pain Therapy and Palliative Care at the Benedictus Hospital Tutzing a teaching hospital of the Technical University Munich and one of the largest and best known Pain Centres in Europe. 
 

Professor Stephan Schug, Anaesthesiology and Pain Medicine, University of Western Australia and Royal Perth Hospital, WA. Professor Schug is Chair of Anaesthesiology in the Pharmacology and Anaesthesiology Unit of the University of Western Australia and Director of Pain Medicine at Royal Perth Hospital, WA. He is a specialist anaesthetist with an MD in pharmacology. His main research interests are in the pharmacology of analgesics and local anaesthetics, the management of acute, chronic and cancer pain, regional anaesthesia and analgesia, organisational structures for pain management and reduction of adverse events in hospitals.

 

Wednesday 18 March 2015, 7.30 - 8.30 am

Is codeine a fait accompli for patients needing more pain relief?
For many patients (and prescribers) codeine-combination analgesics may be the next step in pain relief, that they are unable to avoid, when they need more pain relief. Codeine combinations have a established history of use however they also have well documented challenges. In this session Dr Kubler will review the clinical data for NEW Nuromol® with Synchrotech™ a fixed dose combination of Ibuprofen (200mg) and Paracetamol (500mg). The clinical data supports not only greater efficacy compared to codeine combinations but it will also show you why more patients achieve the pain relief they require taking Nuromol® with Synchrotech™ than any other Over-The-Counter analgesic.

Dr Paul Kubler (MBBS, FRACP) Director of Clinical Pharmacology and Rheumatology at the Royal Brisbane & Women’s Hospital. Retired Chair and Member of the editorial executive committee of Australian Prescriber. External clinical evaluator for the TGA in assessing applications for licensing of new medications, particularly for rheumatic conditions. Member of the Medication Reference Group for the Australian Quality and Safety in Healthcare Council. Providing input to national and local guideline development on the use of medicines for rheumatic disorders. Member of local and state medicines committee responsible for the review of new medicines to be added to hospital/state formulary.


Management of Tendinopathy
Tendinopathy is a common cause of pain in patients ranging from the weekend warrior through to the elite athlete as well as in domestic and repetitive work injuries. There are many conservative treatments available at present but outcomes remain unsatisfactory. This session will focus on discussions regarding pathobiology of tendinopathy and address various biological treatment options for tendinopathy. Clinical evidence of autologous tenocytes injections for tendinopathy will be presented at this session. 

Professor Ming Hao Zheng, MD, PhD, FRCPath, Director. Centre for Translational Orthopaedic Research, School of Surgery, University of Western Australia. Professor Zheng is currently the Winthrop Professor and Director of Research at the Translational Orthopedic Research Centre, Sir Charles Gardner Hospital, Perth and the Associate Dean (International) of the Faculty of Medicine, Dentistry and Health Sciences at the University of Western Australia. He is also the founding member and Consultant Chief Scientific Officer of Orthocell Ltd in Australia, Chung Kong Scholar Lecturing Professor and the Deputy Director of Australia-China Cooperative Research Centre for Biotherapeutics and Regenerative Medicine at the Zhejiang University, Director for UWA-Nanjing Bone and Joint Research Centre at Nanjing University, China. He is a member of the Western Australia Premier’s Award Committee and a member of editorial board for numbers of Orthopedics and Pathology journals, including Stem cell Research & Therapy. He has published more than 150 peer review papers and book chapters and 8 patents in Orthobiologics.

Dr Jane Fitzpatrick is a specialist Sports and Exercise Medicine Physician working in Melbourne. She has been a Fellow of the Australasian College of Sports and Exercise Medicine since 1992 and was the Treasurer of the College for several years. She was a founding member of the International Olympic Committee – Triathlon Medical Commission and the team doctor for the Australian Triathlon Team for 10 years.  Jane is currently the team physician for the Australian Cross Country ski Team and the Medical Director for the Australian Biathlon Team. She is a member of the International Biathlon Union Medical Committee, the Principal Investigator (PI) in Melbourne for Auxilium Pharmaceuticals in a Phase IIb study on frozen Shoulder and PI in a randomised controlled trial using PRP in gluteal tendinopathy. She has a particular interest in new developments in the treatment of osteoarthritis and tendinopathy. 

For further information please contact the APS Secretariat: DC Conferences Pty Ltd
Suite 103, Level 1, 3-5 West Street, North Sydney NSW 2060, Australia | PO Box 637, North Sydney 2059
P 612 9954 4400 | F 612 9954 0666 | E aps2015@dcconferences.com.au